A Phase 2 interventional study of risankizumab and placebo for risankizumab in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-05-21.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 13th largest by enrollment, is one of 6 that started in 2016, is one of 4 in phase 2, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 22nd largest by enrollment of the 48 interventional ones that give a count, is one of 8 that started in 2016, is one of 5 in phase 2, and was the 41st registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
Participants were randomized to receive either placebo, risankizumab 75 mg, or risankizumab 150 mg in Part A. All participants received 2 injections to maintain the blind: the placebo arm received 2 injections of placebo, the risankizumab 75 mg arm received one injection of risankizumab 75 mg and one injection of placebo, and the risankizumab 150 mg arm received 2 injections of risankizumab 75 mg. Participants who received placebo in Part A switched to risankizumab in Part B; participants who received risankizumab (75 mg or 150 mg) in Part A continued to receive the same treatment (risankizumab 75 mg or 150 mg) in Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):
Exclusion Criteria:
Patients with
Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
Drug: placebo for risankizumab
Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
Drug: risankizumab · Drug: placebo for risankizumab
Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
Drug: risankizumab
Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Also known as: ABBV-066, BI 655066
Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving PASI90 at Week 52 (Part B)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 52
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 52
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving PASI75 at Week 52 (Part B)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 52
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants Achieving PASI100 at Week 52 (Part B)
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 52
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)
Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 16
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)
Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
Time frame: Week 52
| Milestone | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|---|---|---|
| Started | 58 | 58 | 55 | 0 | 0 | 0 | 0 |
| Completed | 54 | 58 | 55 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 27 | 27 | 58 | 55 |
| Completed | 0 | 0 | 0 | 27 | 26 | 56 | 54 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Not dosed due to ae | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) |
|---|---|---|---|
| Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) | 1.7 | 75.9 | 74.5 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|
| Percentage of Participants Achieving PASI90 at Week 52 (Part B) | 81.5 | 85.2 | 86.2 | 92.7 |
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) |
|---|---|---|---|
| Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A) | 10.3 | 86.2 | 92.7 |
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|
| Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B) | 96.3 | 88.9 | 84.5 | 94.5 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) |
|---|---|---|---|
| Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A) | 8.6 | 89.7 | 94.5 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|
| Percentage of Participants Achieving PASI75 at Week 52 (Part B) | 100 | 88.9 | 94.8 | 96.4 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) |
|---|---|---|---|
| Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A) | 0 | 22.4 | 32.7 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|
| Percentage of Participants Achieving PASI100 at Week 52 (Part B) | 40.7 | 44.4 | 43.1 | 41.8 |
Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) |
|---|---|---|---|
| Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A) | 0 | 40.0 | 33.3 |
Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.
| percentage of participants | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab150 mg /Risankizumab 150 mg (Part B) |
|---|---|---|---|---|
| Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B) | 100 | 100 | 60.0 | 0 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 16 weeks after the last dose of study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Part A) | 0/58 (0%) | 1/58 (1.7%) | 22/58 (37.9%) |
| Risankizumab 75 mg (Part A) | 0/58 (0%) | 2/58 (3.4%) | 14/58 (24.1%) |
| Risankizumab 150 mg (Part A) | 0/55 (0%) | 2/55 (3.6%) | 14/55 (25.5%) |
| Placebo/Risankizumab 75 mg (Part B) | 0/27 (0%) | 2/27 (7.4%) | 10/27 (37%) |
| Placebo/Risankizumab 150 mg (Part B) | 0/27 (0%) | 0/27 (0%) | 19/27 (70.4%) |
| Risankizumab 75 mg/Risankizumab 75 mg (Part B) | 0/56 (0%) | 1/56 (1.8%) | 23/56 (41.1%) |
| Risankizumab 150 mg/Risankizumab 150 mg (Part B) | 0/54 (0%) | 1/54 (1.9%) | 19/54 (35.2%) |
| Event | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab 150 mg/Risankizumab 150 mg (Part B) |
|---|---|---|---|---|---|---|---|
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/58 | 0/55 | 1/27 | 0/27 | 0/56 | 0/54 |
| Loss of consciousnessNervous system disorders | 0/58 | 0/58 | 0/55 | 1/27 | 0/27 | 0/56 | 0/54 |
| Rectal polypGastrointestinal disorders | 0/58 | 0/58 | 0/55 | 0/27 | 0/27 | 0/56 | 1/54 |
| Acute myocardial infarctionCardiac disorders | 0/58 | 0/58 | 1/55 | 0/27 | 0/27 | 0/56 | 0/54 |
| Erythrodermic psoriasisSkin and subcutaneous tissue disorders | 0/58 | 0/58 | 1/55 | 0/27 | 0/27 | 0/56 | 0/54 |
| Dermal cystSkin and subcutaneous tissue disorders | 0/58 | 0/58 | 0/55 | 0/27 | 0/27 | 1/56 | 0/54 |
| Pneumonia bacterialInfections and infestations | 1/58 | 0/58 | 0/55 | 0/27 | 0/27 | 0/56 | 0/54 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/58 | 1/58 | 0/55 | 0/27 | 0/27 | 0/56 | 0/54 |
| HypotensionVascular disorders | 0/58 | 1/58 | 0/55 | 0/27 | 0/27 | 0/56 | 0/54 |
| Event | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Placebo/Risankizumab 75 mg (Part B) | Placebo/Risankizumab 150 mg (Part B) | Risankizumab 75 mg/Risankizumab 75 mg (Part B) | Risankizumab 150 mg/Risankizumab 150 mg (Part B) |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/58 | 3/58 | 10/55 | 8/27 | 8/27 | 12/56 | 11/54 |
| PsoriasisSkin and subcutaneous tissue disorders | 9/58 | 2/58 | 0/55 | 0/27 | 1/27 | 0/56 | 0/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/58 | 0/58 | 2/55 | 3/27 | 3/27 | 0/56 | 0/54 |
| Dental cariesGastrointestinal disorders | 1/58 | 0/58 | 0/55 | 0/27 | 1/27 | 1/56 | 4/54 |
| VomitingGastrointestinal disorders | 1/58 | 0/58 | 0/55 | 0/27 | 2/27 | 0/56 | 1/54 |
| Oral herpesInfections and infestations | 0/58 | 0/58 | 0/55 | 0/27 | 2/27 | 0/56 | 0/54 |
| Back painMusculoskeletal and connective tissue disorders | 1/58 | 2/58 | 1/55 | 2/27 | 1/27 | 2/56 | 1/54 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/58 | 0/58 | 0/55 | 2/27 | 0/27 | 0/56 | 1/54 |
| AsteatosisSkin and subcutaneous tissue disorders | 0/58 | 0/58 | 0/55 | 2/27 | 0/27 | 0/56 | 0/54 |
| Tinea pedisInfections and infestations | 2/58 | 1/58 | 0/55 | 0/27 | 1/27 | 0/56 | 3/54 |
Intent-to-treat (ITT) population: all participants who were randomized.
| Age, Continuous(years) | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Total |
|---|---|---|---|---|
| Mean | 50.9 ± 11.24 | 51.5 ± 12.33 | 53.3 ± 11.94 | 51.9 ± 11.82 |
| Sex: Female, Male(Participants) | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Total |
|---|---|---|---|---|
| Female | 13 | 10 | 5 | 28 |
| Male | 45 | 48 | 50 | 143 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 58 | 58 | 55 | 171 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo (Part A) | Risankizumab 75 mg (Part A) | Risankizumab 150 mg (Part A) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 58 | 58 | 55 | 171 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Sep 2017, 9 months.
Results were first posted in Feb 2019, 1 year 4 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab